---
title: "港股创维集团尾盘拉升，涨幅扩大至 40%。"
description: "港股创维集团尾盘拉升，涨幅扩大至 40%。"
type: "news"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/256336422.md"
published_at: "2025-09-08T08:06:52.000Z"
---

# 港股创维集团尾盘拉升，涨幅扩大至 40%。

港股创维集团尾盘拉升，涨幅扩大至 40%。

### Related Stocks

- [00751.HK - 创维集团](https://longbridge.com/zh-CN/quote/00751.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 00:16 ETSKYWORTH PV neemt deel aan Expo Greater Amsterdam met zijn SUN Mate-balkonzonnepaneeloplossing | SKYWORTH PV will participate in Expo Greater Amsterdam from March 10-12, 2026, showcasing its SUN Mate balcony solar pan | [Link](https://longbridge.com/zh-CN/news/275995515.md) |
| Skyworth Group Limited's (HKG:751) Top Key Executive Wang Wong is the most upbeat insider, and their holdings increased by 37% last week | Skyworth Group Limited's largest shareholder, Wang Wong, increased his holdings by 37% last week, reflecting significant | [Link](https://longbridge.com/zh-CN/news/273567949.md) |
| Skyworth Group made application to HK Stock Exchange for Skyworth Photovoltaic shares listing | Skyworth Group made application to HK Stock Exchange for Skyworth Photovoltaic shares listing | [Link](https://longbridge.com/zh-CN/news/273069010.md) |
| Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$12.04 From HK$9.11, Keeps at Buy | Nomura Adjusts CSPC Pharmaceutical Group's Price Target to HK$12.04 From HK$9.11, Keeps at Buy | [Link](https://longbridge.com/zh-CN/news/276056763.md) |
| CSPC Pharmaceutical says ropivacaine long-acting injection approved for clinical trials in China | CSPC Pharmaceutical says ropivacaine long-acting injection approved for clinical trials in China | [Link](https://longbridge.com/zh-CN/news/276051793.md) |

---

> **免责声明**：本文内容仅供参考，不构成任何投资建议。